Aussie pot stocks storm higher: Here’s what you need to know

It has been yet another eventful day in the world of Australian pot stocks. After reasonably sharp declines for many of them earlier in the week, they have bounced back strongly today.

Here’s the state of play in the industry today:

The Auscann Group Holdings Ltd (ASX: AC8) share price climbed almost 3% to 58 cents before the company placed its shares in a trading halt pending an announcement. According to the release the announcement is in regards to an update to its Australian operations. Shareholders will no doubt be hopeful this is positive news relating to license application.

The Cann Group Limited (ASX: CAN) share price has exploded higher after hitting the bourse today. Its shares climbed as high as 77 cents in early trade. At present they are up 100% from their 30 cents listing price to 60 cents. With an impressive list of directors and key links with a major Canadian producer, leading hedge fund Tribeca Investment Partners has seen enough potential in the company to invest in its IPO.

The Creso Pharma Ltd (ASX: CPH) share price is down slightly to 58 cents today. Earlier this week Creso Pharma announced that it had imported the first medicinal cannabis products into Australia under new government legislation. Surprisingly the reaction to the news has been relatively subdued.

The Hydroponics Company Ltd (ASX: THC) share price has also rocketed higher on its first day on the ASX boards. At the time of writing its shares are up 82.5% to 36.5 cents. The Hydroponics Company aims to be a leading manufacturer and distributer of cannabis products and equipment.

The MMJ Phytotech Ltd (ASX: MMJ) share price has fallen 16% to 41.5 cents today. Once again, the company’s shares have tumbled despite another huge rally in the shares of its Canada-listed 60%-owned Harvest One Cannabis.

The MGC Pharmaceuticals Ltd (ASX: MXC) share price has edged higher to 5.9 cents. Earlier this week the company announced a collaboration with the Royal Melbourne Institute of Technology on a full suite of medicinal cannabis research initiatives, initially centred on genetics and cultivation.

The Stemcell United Ltd (ASX: SCU) share price has jumped 11.5% to 14.5 cents today despite there being no news out of the company.

The Zelda Therapeutics Ltd (ASX: ZLD) share price is up 4.5% to 9.2 cents. Last month the company announced plans to expand its clinical trials in Chile to cover autism. Management aims to commence the trials in the second-half of the year.

As I have said previously, I do feel one or two of these companies could go on to have great success. But it is still very early days and picking a winner out of a growing pool of companies is very difficult. For this reason I think the majority of investors would be better off watching on from the sidelines for the time being.

In the meantime I think these explosive growth shares would be great options for investors. I'm tipping each of them to smash the market this year.

Top 3 ASX Blue Chips To Buy In 2017

For many, blue chip stocks means stability, profitability and regular dividends, often fully franked..

But knowing which blue chips to buy, and when, can be fraught with danger.

The Motley Fool's in-house analyst team has poured over thousands of hours worth of proprietary research to bring you the names of "The Motley Fool's Top 3 Blue Chip Stocks for 2017."

Each one pays a fully franked dividend. Each one has not only grown its profits, but has also grown its dividend. One increased it by a whopping 33%, while another trades on a grossed up (fully franked) dividend yield of almost 7%.

If you're expecting to see the likes of Commonwealth Bank, Telstra and Wesfarmers shares on this list, you'll be sorely disappointed. Not only are their dividends growing at a snail's pace, their profits are under pressure too due to the increasing competitive environment.

The contrast to these "new breed" blue chips couldn't be greater... especially the very real prospect of significant share price gains, something that's looking less likely from the usual blue chip suspects.

The names of these Top 3 ASX Blue Chips are included in this specially prepared free report. But you will have to hurry. Depending on demand - and how quickly the share prices of these companies moves - we may be forced to remove this report.

Click here to claim your free report.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Two New Stock Picks Every Month!

Not to alarm you, but you’re about to miss a very important event! Chief Investment Advisor Scott Phillips and his team at Motley Fool Share Advisor are about to reveal their latest official stock recommendation. The premium “buy alert” will be unveiled to members and you can be among the first to act on the tip.

Don’t let this opportunity pass you by – this is your chance to get in early!

Simply enter your email now to find out how you can get instant access.

By clicking this button, you agree to our Terms of Service and Privacy Policy. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. You can unsubscribe from Take Stock at anytime. Please refer to our Financial Services Guide (FSG) for more information.